Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael P Boyle

Showing results (71-80 of 91) with videos related to

Pageof 10
Sort By:
Annals of the American Thoracic Society|December 23, 2016
Digitoxin for Airway Inflammation in Cystic Fibrosis: Preliminary Assessment of Safety, Pharmacokinetics, and Dose FindingPamela L Zeitlin, Marie Diener-West, Karen A Callahan, et al.
American Journal of Respiratory Cell and Molecular Biology|April 15, 2006
Respiratory epithelial gene expression in patients with mild and severe cystic fibrosis lung diseaseJerry M Wright, Christian A Merlo, Jeffrey B Reynolds, et al.
Annals of the American Thoracic Society|November 30, 2016
Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del-CFTRSteven M Rowe, Susanna A McColley, Ernst Rietschel, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 1, 2015
Highly compacted biodegradable DNA nanoparticles capable of overcoming the mucus barrier for inhaled lung gene therapyPanagiotis Mastorakos, Adriana L da Silva, Jane Chisholm, et al.
The Journal of Clinical Endocrinology and Metabolism|July 27, 2007
Patients with mutations in Gsalpha have reduced activation of a downstream target in epithelial tissues due to haploinsufficiencyStephanie C Hsu, Joshua D Groman, Christian A Merlo, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 11, 2009
Biodegradable polymer nanoparticles that rapidly penetrate the human mucus barrierBenjamin C Tang, Michelle Dawson, Samuel K Lai, et al.
The Lancet. Respiratory Medicine|June 29, 2014
A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trialMichael P Boyle, Scott C Bell, Michael W Konstan, et al.
Chest|March 12, 2011
Appropriate goal level for 25-hydroxyvitamin D in cystic fibrosisNatalie E West, Noah Lechtzin, Christian A Merlo, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 30, 2014
Overcoming the cystic fibrosis sputum barrier to leading adeno-associated virus gene therapy vectorsBenjamin S Schuster, Anthony J Kim, Joshua C Kays, et al.
American Journal of Speech-Language Pathology|September 13, 2021
Consensus Guidelines for the Assessments of Individuals Who Stutter Across the LifespanShelley B Brundage, Nan Bernstein Ratner, Michael P Boyle, et al.
Pageof 10

Showing results (71-80 of 91) with videos related to

Sort By:
Pageof 10
Annals of the American Thoracic Society|December 23, 2016
Digitoxin for Airway Inflammation in Cystic Fibrosis: Preliminary Assessment of Safety, Pharmacokinetics, and Dose FindingPamela L Zeitlin, Marie Diener-West, Karen A Callahan, et al.
American Journal of Respiratory Cell and Molecular Biology|April 15, 2006
Respiratory epithelial gene expression in patients with mild and severe cystic fibrosis lung diseaseJerry M Wright, Christian A Merlo, Jeffrey B Reynolds, et al.
Annals of the American Thoracic Society|November 30, 2016
Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del-CFTRSteven M Rowe, Susanna A McColley, Ernst Rietschel, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 1, 2015
Highly compacted biodegradable DNA nanoparticles capable of overcoming the mucus barrier for inhaled lung gene therapyPanagiotis Mastorakos, Adriana L da Silva, Jane Chisholm, et al.
The Journal of Clinical Endocrinology and Metabolism|July 27, 2007
Patients with mutations in Gsalpha have reduced activation of a downstream target in epithelial tissues due to haploinsufficiencyStephanie C Hsu, Joshua D Groman, Christian A Merlo, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 11, 2009
Biodegradable polymer nanoparticles that rapidly penetrate the human mucus barrierBenjamin C Tang, Michelle Dawson, Samuel K Lai, et al.
The Lancet. Respiratory Medicine|June 29, 2014
A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trialMichael P Boyle, Scott C Bell, Michael W Konstan, et al.
Chest|March 12, 2011
Appropriate goal level for 25-hydroxyvitamin D in cystic fibrosisNatalie E West, Noah Lechtzin, Christian A Merlo, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 30, 2014
Overcoming the cystic fibrosis sputum barrier to leading adeno-associated virus gene therapy vectorsBenjamin S Schuster, Anthony J Kim, Joshua C Kays, et al.
American Journal of Speech-Language Pathology|September 13, 2021
Consensus Guidelines for the Assessments of Individuals Who Stutter Across the LifespanShelley B Brundage, Nan Bernstein Ratner, Michael P Boyle, et al.
Pageof 10